NEO PanTracer Tissue + HRD
Use
The NEO PanTracer Tissue + HRD test is a comprehensive next-generation sequencing panel designed for the detection of genetic alterations in pan-solid tumors. It identifies single nucleotide variants (SNV), insertions/deletions (InDels), copy number variants (CNV), RNA fusions, and splice variants across a wide range of genes. This test provides crucial insights for the management of ovarian tumors by including the homologous recombination deficiency (HRD) status. Additionally, the test evaluates microsatellite instability (MSI) and tumor mutational burden (TMB), which can guide immunotherapy decisions.
Special Instructions
A block is preferred for testing with >20% tumor and >5 mm2 of tissue surface area for NGS. If using unstained slides, ensure appropriate numbers are submitted based on tissue size. Additional slides may be required if performing PD-L1 testing. NYS clients should provide date and time of specimen collection, and specimens should be transported using a cold pack, avoiding direct contact with the specimen.
Limitations
The test may have limitations in detecting certain types of gene alterations and low-frequency variants. The accuracy of HRD status assessment depends significantly on the quality and type of the sample, such as tumor content and DNA quality. MSI and TMB results rely on the sequencing depth and region coverage; results outside validated ranges may not be available.
Methodology
NGS (CGP)
Biomarkers
Result Turnaround Time
8-10 days
Related Documents
For more information, please review the documents below
Specimen
Tissue (Fresh)
Volume
Not provided
Minimum Volume
Not provided
Collection Instructions
A block is preferred for testing: >20% tumor and >5 mm2 of tissue surface area for NGS (~500 tumor cells). If submitting 5-micron unstained slides, provide the required number of slides based on tissue area.
Storage Instructions
Use cold pack for transport, avoiding direct contact with the specimen.